A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR -/- mouse model.

A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR -/- mouse model.

Item
http://www.wikidata.org/entity/Q33813361
African horse sickness: The potential for an outbreak in disease-free regions and current disease control and elimination techniques.Vaccination of horses with a recombinant modified vaccinia Ankara virus (MVA) expressing African horse sickness (AHS) virus major capsid protein VP2 provides complete clinical protection against challenge.Serotype specific primers and gel-based RT-PCR assays for 'typing' African horse sickness virus: identification of strains from Africa.Immunogenicity of recombinant VP2 proteins of all nine serotypes of African horse sickness virus.Multiserotype protection elicited by a combinatorial prime-boost vaccination strategy against bluetongue virus.Schmallenberg virus infection of adult type I interferon receptor knock-out mice.Protection of IFNAR (-/-) mice against bluetongue virus serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2Ns1 is a key protein in the vaccine composition to protect Ifnar(-/-) mice against infection with multiple serotypes of African horse sickness virus.Real time RT-PCR assays for detection and typing of African horse sickness virusStructural insight into African horsesickness virus infection.Assembly of Replication-Incompetent African Horse Sickness Virus Particles: Rational Design of Vaccines for All SerotypesAn Overview of Animal Models for Arthropod-Borne Viruses.A Crimean-Congo hemorrhagic fever (CCHF) viral vaccine expressing nucleoprotein is immunogenic but fails to confer protection against lethal disease.VP2 Exchange and NS3/NS3a Deletion in African Horse Sickness Virus (AHSV) in Development of Disabled Infectious Single Animal Vaccine Candidates for AHSV.Structural Protein VP2 of African Horse Sickness Virus Is Not Essential for Virus Replication In Vitro.The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host.A single dose of African horse sickness virus (AHSV) VP2 based vaccines provides complete clinical protection in a mouse model
P2860

A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR -/- mouse model.

Item
http://www.wikidata.org/entity/Q33813361
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A modified vaccinia Ankara vir ...... e in an IFNAR -/- mouse model.
@ast
A modified vaccinia Ankara vir ...... e in an IFNAR -/- mouse model.
@en
type
label
A modified vaccinia Ankara vir ...... e in an IFNAR -/- mouse model.
@ast
A modified vaccinia Ankara vir ...... e in an IFNAR -/- mouse model.
@en
prefLabel
A modified vaccinia Ankara vir ...... e in an IFNAR -/- mouse model.
@ast
A modified vaccinia Ankara vir ...... e in an IFNAR -/- mouse model.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P932
P356
P1433
P1476
A modified vaccinia Ankara vir ...... ge in an IFNAR -/- mouse model
@en
P2093
P2860
P304
P31
P356
10.1371/JOURNAL.PONE.0016503
P407
P433
P478
P50
P577
P5875
P698
P932